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Background: The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-
positive acute lymphoid leukemia (Ph + ALL) patients. Resistant T315I clone may be present prior to initiating
dasatinib, which could expand under selective pressures during treatment. However, it is also possible that Ph + ALL
patients newly acquire the T315I mutation during dasatinib therapy. Despite the potent inhibition of BCR-ABL
kinase by dasatinib, little is known about the relationship between dasatinib pharmacokinetics and the emergence
of kinase domain mutations in vivo.
Methods: To determine whether plasma dasatinib pharmacokinetics influences the emergence of BCR-ABL
mutations, we measured plasma dasatinib levels in 11 Ph + ALL patients undergoing dasatinib monotherapy.
Results: Bone marrow relapse occurred in 5 of the 11 Ph+ALL patients (45%). Importantly, a T315I mutation was
detected in 4 of the 5 relapsed patients, despite the absence of BCR-ABL mutations in any patient at baseline. The
median plasma concentration at 2 hours (C2h), the median plasma maximum concentration (Cmax), and the median
area under the observed plasma concentration-time curve from 0 to 4 hours (AUC0-4) were all significantly lower in
patients with T315I than those without the mutation (C2h, 22.3 ng/mL vs. 111.6 ng/mL, P= 0.0242; Cmax, 43.8 ng/mL
vs. 112.4 ng/mL, P= 0.0242; AUC0-4, 108.3 ng•h/mL vs. 268.3 ng•h/mL, P= 0.0061, respectively).
Conclusions: These data indicate that the emergence of the T315I mutation among Ph +ALL patients treated with
dasatinib is, in part, dependent on plasma dasatinib pharmacokinetics. Notably, these data also suggest that newly
acquired BCR-ABL mutations may be inhibited by an increased exposure of dasatinib.
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Dasatinib is a second-generation inhibitor of the BCR-ABL
and SRC tyrosine kinases. In vitro, dasatinib inhibits the
BCR-ABL kinase with 325-fold greater potency than imati-
nib [1]. In addition, it showed significant activity in Phase II
studies in Philadelphia-positive acute lymphoid leukemia
(Ph+ALL) patients who were resistant or intolerant to ima-
tinib [2]. In pharmacokinetic studies, dasatinib exposure
was shown to vary linearly and proportionally with dose.
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reproduction in any medium, provided the orhours after a single oral administration, and the mean ter-
minal elimination half-life (t 1/2) was <4 hours with rapid
absorption.
Dasatinib has in vitro activity against all imatinib-
resistant BCR-ABL mutations, with the notable exception
of T315I [1]. For example, a previous study reported that
12 of 17 relapsed Ph+ALL patients acquired a T315I mu-
tation during dasatinib therapy [3]. Additionally, there is
little data on the relationship between plasma dasatinib
concentration and outcome or adverse events, and no clin-
ically relevant data to suggest that dose changes are neces-
sary based on sex, age, or pharmacogenetic variation in
dasatinib transporters. Moreover, little is known about the
relationship between dasatinib pharmacokinetics and the
emergence of BCR-ABL kinase domain mutations in vivo.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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performance liquid chromatography (HPLC) to measure




Plasma dasatinib concentrations prior to therapy and 1
to 4 hours after administration (C0h, C1h, C2h and C4h)
on day 7, which previously has been found to represent
a stable period of dasatinib pharmacokinetics [4], were
measured by HPLC. Pharmacokinetic analyses of dasati-
nib were performed using the standard non-
compartmental method with WinNonlin (Pharsight Co.,
Mountain View, CA, version 4.0.1). The area under the
observed plasma concentration-time curve from 0 to 4
hours (AUC0-4) was calculated using the linear trapez-
oidal rule. Cmax was obtained directly from the profile.
BCR-ABL Mutation analyses
Peripheral blood samples were obtained at baseline of
dasatinib initiation and at bone marrow relapse. The
bcr-abl fusion transcript was analyzed for mutations
using direct sequencing.
Statistical analyses
Statistical analyses were carried out using SPSS (SPSS
Japan Inc., Tokyo, Japan, version 17.0) and the data are
presented as medians (quartile 1-quartile 3). Differences
in reported parameters between two patient groups were
evaluated using the Mann-Whitney's U test. Time to
event was measured from the date of dasatinib adminis-
tration to the date of hematological relapse, date of
death from any cause, or date of last molecularTable 1 Patients and clinical outcomes with dasatinib monoth
No Age Sex Dasatinib dose BM relapse BCR-
1 56 M 100 mg QD No
2 56 M 100 mg QD No
3 64 F 100 mg QD No
4 68 M 100 mg QD Yes
5 67 F 100 mg QD Yes
6 22 F 100 mg QD No
7 77 M 50 mg BID Yes
8 63 F 50 mg QD Yes
9 80 F 100 mg QD No
10 32 M 100 mg QD No
11 78 M 100 mg QD Yes
BM, bone marrow; EFS, event-free survival; OS, overall survival; M, male; F, femal; QD
molecular response; PD, progressive disease; * a date of SCT was evaluated as censexamination for patients who did not relapse. Event-free
survival (EFS) was estimated using the Kaplan- Meier
method. Values of P< 0.05 were considered significant.Study conduct
The study was conducted in accordance with the
Declaration of Helsinki. Informed consent was obtained
from all patients according to institutional guidelines.
The study was approved by the Akita University
Research Ethics Board.Results
Eleven patients with Ph +ALL received dasatinib mono-
therapy as an induction therapy according to previous
study reported by Foà et al [3] (Table 1). The mean age
was 59.0 years (range: 22–80 years), and 54.5% of the
patients were male. No patient had severe hepatic or
renal dysfunction. Median treatment duration of dasati-
nib monotherapy was 221 days (151.3-355.5 days).
There were no CNS leukemia or CNS relapses among
any of the patients during dasatinib monotherapy and all
patients achieved hematological remission; however, bone
marrow relapse was observed in 5 of the 11 Ph+ALL
patients (45%). Importantly, a T315I mutation was detected
in 4 of the 5 relapsed patients by direct sequencing, despite
the absence of BCR-ABL mutations in any patient at
baseline. The median EFS for Ph+ALL patients with T315I
was 197 days. In contrast, the median EFS for patients
without T315I had not yet been reached, and the estimated
20-month survival rate was 70%.
Table 2 summarizes the comparison between clinical
characteristics and dasatinib pharmacokinetics in patients
with and without T315I during dasatinib therapy. With the
exception of platelet count, no correlations were detected
with any clinical characteristics and T315I emergence;erapy
ABL mutation EFS, day Outcome / Event (cause of death)
No 624* SCT in CMR
No 149 dead (infection)
No 318 CMR
T315I 368 dead (PD)
T315I 197 dead (PD)
No 634* SCT in CMR
T315I 221 dead (PD)
T315I 106 dead (PD)
No 269 CMR
No 158 CMR
No 114 dead (PD)
, once a day; BID, twice a day; SCT, stem cell transplantation; CMR, complete
oring for analysis of EFS.
Table 2 Comparison of the clinical characteristics and dasatinib pharmacokinetics in patients with and without a T315I
mutation
T315I (n = 4) Without T315I (n = 7) P-Value
median (quartile 1- quartile 3) median (quartile 1- quartile 3)
Sex † Female 2 (50.0) 3 (42.9) 0.6515
Age (year) 67 (64–72) 56 (38.5 - 71) 0.4121
Bodily weight (kg) 50.3 (48.3 - 60.1) 49.0 (44.2 - 52.8) 0.7879
Body surface area (m2) 1.49 (1.46 - 1.57) 1.45 (1.39 - 1.57) 0.6485
White blood cell (*103/mm3) 2.4 (2.4 - 2.5) 3.7 (2.15 - 5.85) 0.3833
Red blood cell (*104 mm3) 248 (241–282) 291 (238–316) 0.8333
Platelet (*104 /mm3) 70 (50.5 - 77.5) 135 (117–167) 0.0167
Aspartate transaminase (IU/L) 32.5 (19.5 - 50) 33 (15.5 - 34) 0.5273
Alanine transaminase (IU/L) 23 (21–79) 23 (14–73.5) 0.7879
Serum albumin (g/dL) 4.3 (4.0 - 4.5) 3.9 (3.3 - 4.2) 0.2303
Total bilirubin (mg/dL) 0.4 (0.4 - 0.5) 0.4 (0.4 - 0.9) 0.9273
Serum creatinine (mg/dL) 0.6 (0.5 - 0.8) 0.6 (0.5 - 0.9) 0.7879
Single dose (mg) 100 (75–100) 100 (100–100) 0.7879
C0h (ng/mL) 0.2 (0.1 - 0.4) 0.0 (0.0 - 0.0) 0.1091
C1h (ng/mL) 13.2 (3.3 - 23.8) 49.0 (23.6 - 66.7) 0.0727
C2h (ng/mL) 22.3 (5.8 - 43.8) 111.6 (65.1 - 122.8) 0.0242
C4h (ng/mL) 34.6 (10.6 - 76.3) 69.7 (66.9 - 95.3) 0.1636
Cmax (ng/mL) 43.8 (19.1 - 77.0) 112.4 (95.3 - 122.8) 0.0242
AUC0-4h (ng•h/mL) 108.3 (49.2 - 139.2) 268.3 (220.0 - 307.3) 0.0061
† Data presented as numbers (%) of patients;
Cnh, plasma concentration at n hour after dasatinib administration;
Cmax, maximum plasma concentration less than 4 hours after dasatinib administration;
AUC0-4h, area under the plasma concentration-time curve from 0 to 4 hours.
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Figure 1 Comparison of clinical and pharmacokinetic parameters of d
(A) plasma concentration 2 h after dasatinib administration (C2h), (B)
(Cmax), and (C) area under the plasma concentration-time curve from
median represented by bold horizontal lines. The ends of the whiskers (ver
outliers.Discussion
The emergence of a BCR-ABL kinase domain mutation
during dasatinib therapy, particularly T315I, is a signifi-


















Without T315IWithout T315I T315I
 0.0242
asatinib in patients with and without a T315I mutation:
maximum plasma concentration after dasatinib administration
0 to 4 h (AUC0-4h). Boxes represent interquartile ranges (IQR) with the
tical lines) represent the smallest and largest values that are not
Takahashi et al. Journal of Hematology & Oncology 2012, 5:23 Page 4 of 4
http://www.jhoonline.org/content/5/1/23clinical management. The median time between dasati-
nib treatment initiation and T315I mutation detection in
our study was 7.4 months (range, 3.5-12.3 months),
which was similar to the 9.1 months reported in a previ-
ous retrospective study by Nicolini et al. [5].
Soverini et al. retrospectively analyzed Ph +ALL
patients treated with dasatinib by cloning the BCR-ABL
kinase domain in a bacterial vector and sequencing 200
independent clones per sample. Notably, T315I was
detected at diagnosis in two of six patients who relapsed
[6]. Although a T315I mutation could exist prior to
dasatinib treatment, evidence from both clinical trials [3]
and mouse models [7] indicates that in some cases it is
newly acquired as a result of selective pressures during
treatment. If a resistant T315I clone was present prior to
dasatinib treatment, it would likely expand under select-
ive pressures, and its prevention likely requires a novel
agent targeting T315I leukemia. However, if a resistant
T315I clone was newly acquired during proliferation due
to insufficiency of dasatinib therapy, it may be possible
to prevent acquired genetic tyrosine kinase mutations by
an increased exposure of dasatinib.
An effective transient dasatinib level of 100 nM (ap-
proximately 50 ng/mL) is sufficient to inhibit the in vitro
proliferation of most cell lines expressing imatinib-
resistant BCR-ABL mutations, with the exception of
T315I [8]. In vivo, the effective transient dasatinib level
might represent a concentration sufficient to inhibit the
proliferation of primary ALL cells prior to the emer-
gence of T315I. Our data suggest that a plasma dasatinib
concentration that inhibits proliferation of Ph + cells and
induces apoptosis might inhibit the emergence of BCR-
ABL mutations, including T315I, when a resistant T315I
clone is not present prior to dasatinib treatment.
In conclusion, lower plasma concentrations of dasati-
nib were detected among Ph +ALL patients with T315I
compared to those without the mutation. These data
suggest that sufficient exposure of dasatinib may pro-
hibit clonal evolution by adequately inhibiting BCR-ABL
kinase. Future prospective studies with larger sample
sizes of Ph +ALL patients are warranted to confirm
these results.
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